ResMed (NYSE: RMD) reported Q1 EPS of $0.66, in-line with the analyst estimate of $0.66. Revenue for the quarter came in at $523.7 million versus the consensus estimate of $505.61 million.

For earnings history and earnings-related data on ResMed (RMD) click here.